Literature DB >> 20206668

Codon-optimization of the hemagglutinin gene from the novel swine origin H1N1 influenza virus has differential effects on CD4(+) T-cell responses and immune effector mechanisms following DNA electroporation in mice.

M Tenbusch1, T Grunwald, T Niezold, M Storcksdieck Genannt Bonsmann, D Hannaman, S Norley, K Uberla.   

Abstract

DNA electroporation is a powerful vaccine strategy that could be rapidly adapted to address emerging viruses. We therefore compared cellular and humoral immune responses in mice vaccinated with DNA expression plasmids encoding either the wildtype or a codon-optimized sequence of hemagglutinin from the novel swine origin H1N1 influenza virus. While expression of HA from the wildtype sequence was hardly detectable, the H1N1 hemagglutinin was well expressed from the codon-optimized sequence. Despite poor expression of the wildtype sequence, both plasmids induced similar levels of CD4(+) T-cell responses. However, CD8(+) T-cell and antibody responses were substantially higher after immunization with the codon-optimized DNA vaccine. Thus, efficient induction of immune effector mechanisms against HA of the novel H1N1 influenza virus requires codon-optimization of the DNA vaccines. Since DNA vaccines and several viral vector vaccines employ the same cellular RNA-Polymerase II dependent expression pathway, the poor expression levels from wildtype HA sequences might also limit the induction of immune effector mechanisms by such viral vector vaccines. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20206668     DOI: 10.1016/j.vaccine.2010.02.090

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  14 in total

1.  DNA vaccines encoding DEC205-targeted antigens: immunity or tolerance?

Authors:  Thomas Niezold; Michael Storcksdieck Genannt Bonsmann; André Maaske; Vladimir Temchura; Vanessa Heinecke; Drew Hannaman; Jan Buer; Christina Ehrhardt; Wiebke Hansen; Klaus Überla; Matthias Tenbusch
Journal:  Immunology       Date:  2015-04-30       Impact factor: 7.397

2.  Development of live-attenuated arenavirus vaccines based on codon deoptimization of the viral glycoprotein.

Authors:  Benson Y H Cheng; Aitor Nogales; Juan Carlos de la Torre; Luis Martínez-Sobrido
Journal:  Virology       Date:  2016-11-14       Impact factor: 3.616

Review 3.  The future of human DNA vaccines.

Authors:  Lei Li; Fadi Saade; Nikolai Petrovsky
Journal:  J Biotechnol       Date:  2012-09-07       Impact factor: 3.307

Review 4.  Novel strategies for development of hemorrhagic fever arenavirus live-attenuated vaccines.

Authors:  Luis Martinez-Sobrido; Juan Carlos de la Torre
Journal:  Expert Rev Vaccines       Date:  2016-05-13       Impact factor: 5.217

5.  Targeting antibody responses to the membrane proximal external region of the envelope glycoprotein of human immunodeficiency virus.

Authors:  Donatien Kamdem Toukam; Matthias Tenbusch; Alexander Stang; Vladimir Temchura; Michael Storcksdieck Genannt Bonsmann; Bastian Grewe; Stefanie Koch; Andreas Meyerhans; Godwin Nchinda; Lazare Kaptue; Klaus Uberla
Journal:  PLoS One       Date:  2012-05-30       Impact factor: 3.240

6.  Genomic adaptation of the ISA virus to Salmo salar codon usage.

Authors:  Mario Tello; Francisco Vergara; Eugenio Spencer
Journal:  Virol J       Date:  2013-07-05       Impact factor: 4.099

Review 7.  Synthetic DNA vaccines: improved vaccine potency by electroporation and co-delivered genetic adjuvants.

Authors:  Seleeke Flingai; Matias Czerwonko; Jonathan Goodman; Sagar B Kudchodkar; Kar Muthumani; David B Weiner
Journal:  Front Immunol       Date:  2013-11-04       Impact factor: 7.561

8.  Vaccinia and influenza A viruses select rather than adjust tRNAs to optimize translation.

Authors:  Mariana Pavon-Eternod; Alexandre David; Kimberly Dittmar; Peter Berglund; Tao Pan; Jack R Bennink; Jonathan W Yewdell
Journal:  Nucleic Acids Res       Date:  2012-12-18       Impact factor: 16.971

9.  Protective efficacy and immunogenicity of a combinatory DNA vaccine against Influenza A Virus and the Respiratory Syncytial Virus.

Authors:  Viktoria Stab; Sandra Nitsche; Thomas Niezold; Michael Storcksdieck Genannt Bonsmann; Andrea Wiechers; Bettina Tippler; Drew Hannaman; Christina Ehrhardt; Klaus Uberla; Thomas Grunwald; Matthias Tenbusch
Journal:  PLoS One       Date:  2013-08-14       Impact factor: 3.240

Review 10.  Exploiting tRNAs to Boost Virulence.

Authors:  Suki Albers; Andreas Czech
Journal:  Life (Basel)       Date:  2016-01-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.